Q-omics provides the consensus-scored RBM12B-AS1 profile across patient tissues and cancer cell-line models. RBM12B-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RBM12B-AS1 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, RBM12B-AS1 RNA expression shows 19,932 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, HNSC, and KIRP as cancer lineages where RBM12B-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM12B-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM12B-AS1 survival associations across molecular data types. RBM12B-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM12B-AS1 RNA expression–survival associations across cancer types. High RBM12B-AS1 expression shows unfavorable associations in THCA, UVM, ACC, COAD and KIRP, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for RBM12B-AS1 RNA expression.
This table summarizes RBM12B-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBM12B-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM12B-AS1 shows higher tumor expression in HNSC, BLCA, LUAD, KIRC, STAD and UCEC. The HNSC box plot shows higher RBM12B-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.738, t-test p < 0.001).
This table shows molecular features associated with RBM12B-AS1 in patient tissues and cancer cell lines. In patient samples, RBM12B-AS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM12B-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in NCI60_ALL.
